Lintuzumab

Drug Profile

Lintuzumab

Alternative Names: Anti-CD33 MAb; HuM 195; SGN-33

Latest Information Update: 15 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Developer Seattle Genetics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD33 antigen inhibitors; Cytokine inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 13 Sep 2010 Discontinued - Phase-I for Myelodysplastic syndromes in USA (IV)
  • 13 Sep 2010 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
  • 09 Jun 2009 Efficacy and safety data from a phase I trial in acute myeloid leukaemia and myeloproliferative diseases presented at the 14th Congress of the European Hematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top